New members will help commercialize innovative technologies for early lung
ALBUQUERQUE, N.M., May 5 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical diagnostics company, today announced the election of three business leaders, Maria Zannes, David Lambros, and Lewis White, to its Board of Directors. The Board Members' terms as Directors began May 1.
"We are pleased to engage these leaders' keen business expertise and
apply their high levels of practical and regulatory experience in the
interests of Biomoda shareholders," said John Cousins, Biomoda president.
"With their involvement, Biomoda is in an ideal position to influence the
future of technology for early diagnosis and treatment of lung cancer
throughout the world."
-- Maria Zannes brings more than 25 years of experience in the
environmental and energy industry -- from federal lobbyist to company
president. Formerly the president of the national waste-to-energy
trade group in Washington, D.C., Zannes currently consults for private
clients in the medical and waste industry. She was a legislative aide
and press secretary to Congressman Charles Wilson (D-Texas) after
leaving her home state of New Mexico where she began her career as a
journalist. Zannes is licensed to practice law in Washington State and
will be sworn into practice in New Mexico this summer
-- David Lambros was the elected law director of Brook Park, Ohio, and
presently serves the law director of the Village of Valley View and
the Village of Kelleys Island, Ohio. As law director, he served as the
chief legal counsel to cities negotiating with corporations and
business, and is an expert in municipal law. Lambros has practiced law
for more than 25 years and served on various boards, including
Commerce Exchange Bank and Southwest General Hospital. As a board
member of Commerce Exchange Bank, he was instrumental in raising share
value of the stock from $2.00 to a sale price of $13.00. He presently
is a director on the Systems Board at Southwest General Hospital, a
multi-million dollar company.
-- Lewis White, a major shareholder in Biomoda, is director and CEO of
New Energies Nebraska, LLC, a subsidiary of Standard Alcohol Company.
He has also served as CEO of Los Hojas Corporation and owned a
successful childcare business for 20 years, which he followed with an
interest in business investment through real estate and a thriving
food services business catering to niche markets. White attended the
University of Nebraska at Omaha where majored in Business
Administration and worked for the State of Nebraska.
With Biomoda's technology, clinicians can identify cancerous or aberrant cells extracted from samples of lung sputum; cancerous cells glow red under fluorescent light and can be detected under a microscope. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease at more advanced stages. Biomoda's technology complements these tools by screening for signs of lung cancer at an earlier stage, ensuring that patients receive advanced tests at the appropriate time.
Earlier this year, Biomoda and the New Mexico Institute of Mining and Technology announced their partnership with the New Mexico Department of Veterans Services to conduct a $350,000 clinical study using Biomoda's proprietary testing technology for detection of early lung cancer in the state's veterans. The New Mexico state legislature recently allocated an additional $1.3 million in funding through the Interim Tobacco Settlement Committee to the clinical screening program.
Lung cancer claims more lives than any other cancer. The expected
five-year survival rate for all patients diagnosed with lung cancer is 15
percent; the five-year survival rate for cases detected when the disease is
still localized is 50 percent. Presently, only 16 percent of lung cancer
cases are diagnosed at this early stage.
Biomoda's technology was originally developed at Los Alamos National
For more information contact:
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Biomoda's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. Biomoda, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Biomoda's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
|SOURCE Biomoda, Inc.|
Copyright©2008 PR Newswire.
All rights reserved